Therapeutic Use of a Selective S1P(1) Receptor Modulator Ponesimod in Autoimmune Diabetes

In the present study, we investigated the therapeutic potential of a selective S1P(1) receptor modulator, ponesimod, to protect and reverse autoimmune diabetes in non-obese diabetic (NOD) mice. Ponesimod was administered orally to NOD mice starting at 6, 10, 13 and 16 weeks of age up to 35 weeks of...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Sylvaine, Piali, Luca, Kuhn, Chantal, Steiner, Beat, Sauvaget, Virginia, Valette, Fabrice, Clozel, Martine, Bach, Jean-François, Chatenoud, Lucienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811978/
https://www.ncbi.nlm.nih.gov/pubmed/24204793
http://dx.doi.org/10.1371/journal.pone.0077296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811978/
https://www.ncbi.nlm.nih.gov/pubmed/24204793
http://dx.doi.org/10.1371/journal.pone.0077296

Ejemplares similares